Notes
THEY CALL THAT NATURAL? AN ANALYSIS
OF THE TERM “NATURALLY OCCURRING”
AND THE APPLICATION OF GENES TO THE
PATENT ACT
I. INTRODUCTION
The controversy over the patentability of human genes has existed
for decades.1 Improper monopolization of nature remains one of the
main challenges to the patentability of genes. 2 The comments to the
United States Patent Act (“Patent Act”) state that naturally occurring
substances are not patentable subject matter. 3 However, the federal
1
See Lisa Kole & David Loretto, Patent Law Evolving to Meet Bioinformatics: Genomics
Revolution has Spawned Innumerable Patentable Inventions, but Pitfall Exists, 231 NEW L.J. 1, 3
(2004); Burton T. Ong, Patenting Biological Bounty of Nature: Re-examining the Status of
Organic Inventions as Patentable Subject Matter, 8 MARQ. INTELL. PROP. L. REV. 1, 2 (2004)
(noting that this controversy not only surrounds the patentability of genes, but also the
patentability of other biotechnological subject matter including tissue culture, genetically
altered microorganisms, and multicellular mammalian life forms).
2
Kole, supra note 1, at 3.
3
See 35 U.S.C.S. § 101 note 41 (LexisNexis 2000); see also infra note 68 (discussing that
phenomena of nature are not patentable because they are the basic tools of scientific
research and technological work); infra note 69 (discussing that natural phenomena are not
the kind of discoveries that 35 U.S.C. § 101 was enacted to protect). Compare infra note 70
(discussing the theory that laws of nature are free to all men and reserved exclusively to
none), with 35 U.S.C. § 103 (2000). Section 103 specifically states the requirement of
nonobviousness as follows:
(a) A patent may not be obtained though the invention is not
identically disclosed or described as set forth in section 102 of this title,
if the differences between the subject matter sought to be patented and
the prior art are such that the subject matter as a whole would have
been obvious at the time the invention was made to a person having
ordinary skill in the art to which said subject matter pertains.
Patentability shall not be negatived by the manner in which the
invention was made.
(b) (1) Notwithstanding subsection (a), and upon timely election by the
applicant for patent to proceed under this subsection, a
biotechnological process using or resulting in a composition of matter
that is novel under section 102 and nonobvious under subsection (a) of
this section shall be considered nonobvious if—
(A) claims to the process and the composition of matter are
contained in either the same application for patent or in separate
applications having the same effective filing date; and
(B) the composition of matter, and the process at the time it was
invented, were owned by the same person or subject to an obligation
of assignment to the same person.
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circuit and Supreme Court have maneuvered around this obstacle by
holding that naturally occurring substances, when purified and isolated
from their natural environment, become patentable subject matter
because they have been manipulated by the inventor and are no longer
in their natural state.4 Furthermore, § 103 of the Patent Act specifically
allows for a patent to issue on nucleotides, which are the natural

(2) A patent issued on a process under paragraph (1) —
(A) shall also contain the claims to the composition of matter used
in or made by that process, or
(B) shall, if such composition of matter is claimed in another
patent, be set to expire on the same date as such other patent,
notwithstanding section 154.
(3) For purposes of paragraph (1), the term “biotechnological
process” means—
(A) a process of genetically altering or otherwise inducing a
single- or multi-celled organism to—
(i) express an exogenous nucleotide sequence,
(ii) inhibit, eliminate, augment, or alter expression of an
endogenous nucleotide sequence, or
(iii) express a specific physiological characteristic not naturally
associated with said organism;
(B) cell fusion procedures yielding a cell line that expresses a
specific protein, such as a monoclonal antibody; and
(C) a method of using a product produced by a process defined
by subparagraph (A) or (B), or a combination of subparagraphs (A)
and (B).
35 U.S.C. § 103.
4
See In re Bergstrom, 427 F.2d 1394, 1401–02 (1970); see also DONALD S. CHISUM, CHISUM
ON PATENTS 61 (2004) (discussing that the naturally occurring bar is sometimes used as a
last resort to disqualify matter as patentable under the novelty and nonobviousness
requirement of the patent act); see infra notes 115–20 and accompanying text (discussing
that isolated and purified biological products qualify as new products to fulfill the novelty
requirement for eligible patent material). The novelty requirement consists of the
following:
A person shall be entitled to a patent unless—
(a) the invention was known or used by others in this country, or
patented or described in a printed publication in this or a foreign
country, before the invention thereof by the applicant for patent, or
(b) the invention was patented or described in a printed publication in
this or a foreign country or in public use or on sale in this country,
more than one year prior to the date of the application for patent in the
United States, or
....
(f) he did not himself invent the subject matter sought to be patented[.]
35 U.S.C. § 102 (2000). Isolation is defined as a procedure in which an organism present in
an environment is obtained in pure culture. Life Science Dictionary, http://biotech.icmb.
utexas.edu/search/dict-search.mhtml (last visited Jan. 3, 2006). Purification is defined as
the process of isolating a product into a pure form. Biology Online, http://www.biologyonline.org/dictionary.asp (last visited Jan. 3, 2006).
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building blocks of genes.5 Regardless of this precedent, commentators
continue to argue that manipulation of a natural object does not alter its
natural state and therefore genes should be removed from patentable
subject matter.6
The problem with the federal circuit and Supreme Court’s reasoning
can best be exemplified by the following comparison.7 Compare a field
of grass to a strand of DNA. Furthermore, compare a blade of grass to a
gene. While the blade of grass remains in the field, it is in its natural
environment.8 Similarly, while a gene is attached to its DNA strand, it
also is in its natural environment.9 Both the blade of grass as well as the
gene can be said to be naturally occurring.10 When the blade of grass is
plucked from its root, it has been isolated from the rest of the field.11
Comparably, a gene becomes isolated when it is purified from its DNA
strand.12 In the situation of the blade of grass, one can hardly argue that
the blade extracted from the field is a completely different blade of grass
than when it was still attached to the ground.13 However, in the case of a
gene, the United States Patent and Trademark Office (“USPTO”) has
stated that an excised gene is not the same as a gene in its natural
environment; the process of pulling the gene from its environment
presumably results in such manipulation that it is no longer naturally
occurring.14
The current understanding of the implication of the term “naturally
occurring” on the Patent Act is the nucleus of the argument this Note
presents. 15 The Supreme Court has held that an object is naturally

5
See supra note 3 (discussing the incorporation of nucleotides into the Patent Act); see
infra notes 45–47 and accompanying text (defining a nucleotide).
6
See infra notes 17–18 and accompanying text (discussing the theory that genes are not
naturally occurring and the United States Patent and Trademark Office’s response to this
argument).
7
This hypothetical attempts to compare a naturally occurring microscopic object with a
naturally occurring macroscopic object in order to demonstrate that even though
manipulation has occurred, the macroscopic object is still the same object.
8
See infra Part II.E (discussing the meaning of natural).
9
See infra Part II.B (discussing the natural environment of a gene).
10
See infra Part II.E (discussing the meaning of natural).
11
See infra notes 114–22 and accompanying text (discussing the process of isolation and
purification).
12
See infra notes 114–22 and accompanying text.
13
On a macroscopic level, it is much easier to understand that the two are the same, the
blade still attached to the ground and the blade once severed from the ground.
14
See infra note 17 and accompanying text (discussing the theory that genes are not
naturally occurring and the USPTO’s response to this argument).
15
See infra Parts II.E, III.A.
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occurring when it has the same effect it always has, there is no greater
utility created by the manipulation, and the subject performs in its own,
naturally-determined manner. 16
The USPTO has narrowed the
application of genes to this holding by qualifying genes as compositions
of matter and thus patentable under the Patent Act.17 However, critics of
this argument have qualified genes as naturally occurring on the basis
that owning life is a form of secular sacrilege.18 There is an extreme need
to determine what constitutes a natural substance and is therefore not
patentable under the Patent Act.19 Because biotechnology is constantly
progressing, the Patent Act must be amended to clearly define a
composition of matter so as to exclude naturally occurring genes from
patentable subject matter.20
Part II of this Note discusses current definitions of the terms “gene”
and “natural” followed in congressional and judicial reasoning
concerning these terms and their application to § 101 and § 103 of the
Patent Act.21 It concludes with policy arguments emphasizing the need
16
See Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 131 (1948) (discussing that
bacteria taken from the nodules of certain plants were naturally occurring and thus not
patentable subject matter).
17
See Utility Examination Guidelines, 66 Fed. Reg. 1093, 1093 (Jan. 5, 2001). The USPTO
strengthened this argument by stating that an excised gene is eligible for a patent because
the DNA molecule does not naturally occur in an isolated form in nature. Id. In support of
this argument, the USPTO stated that gene excision is not a new process and that the
patentability of excised products of nature is well established. Id. The USPTO cited to
several authorities to strengthen its opinion that genes are patentable. Id. First, in 1873 a
patent was issued for a form of yeast that was free from all organic forms of germs and
therefore was not naturally occurring. U.S. Patent No. 141,072 (issued July 22, 1873). Next,
the USPTO alluded to a Supreme Court case holding that adrenaline was patentable subject
matter because adrenaline does not occur in nature in a purified form. Utility Examination
Guidelines, 66 Fed. Reg. at 1093 (quoting Parke-Davis & Co. v. H.K. Mulford Co., 189 F. 95
(S.D.N.Y. 1911)). The USPTO concluded that the Supreme Court decision established that
even if the patentable subject matter were merely extracted from a product without a
change in its composition, it would still be patentable upon extraction because it became a
new object. Id. The USPTO relied on another case to determine that genes are patentable
because they do not exist in a pure form in nature. Utility Examination Guidelines, 66 Fed.
Reg. at 1093 (quoting In re Bergstrom, 427 F.2d 1394 (C.C.P.A. 1970)). The comparison
drawn here was between purified prostaglandins and purified genes. Id. In re Bergstrom
established that prostaglandins do not exist in nature in a pure and isolated form and are
patentable. Id. Therefore, the argument made by the USPTO is that genes do not exist in a
pure form in nature and are also patentable. Id. The USPTO concluded this argument on
the basis of prior case law and stated a patent on a gene covers the isolated and purified
form of the gene because such form of the gene does not occur in nature. Id.
18
See Ong, supra note 1, at 4; see also Robert P. Merges, Intellectual Property in Higher Life
Forms: The Patent System and Controversial Technologies, 47 MD. L. REV. 1051, 1058–60 (1988).
19
See infra Part III.A.
20
See infra Part IV.
21
See infra Part II.

2006]

Applying Genes to the Patent Act

747

to excise genes from the category of patentable subject matter.22 Part III
addresses the concern raised by allowing genes to be patentable subject
matter and attempts to establish that genes should not be included
because they are naturally occurring entities. 23 Part IV proposes an
amendment to § 103 of the Patent Act to be utilized when determining
whether an object is naturally occurring.24
II. BACKGROUND
This Note analyzes several relevant topics in order to adequately
address whether genes should be considered patentable subject matter.25
To begin, an explanation of the historical and definitional analysis of a
gene as applied to the Patent Act establishes the manner in which the
USPTO treats the patentability of genes.26 Furthermore, case law dealing
with products of nature explain the current understanding of patentable
subject matter.27 Philosophical arguments concerning the term “nature”
are also introduced to demonstrate more traditional understandings of
the term that aid in appropriately addressing the ethical issues involved

See infra Part II.G.
See infra Part III.
24
See infra Part IV.
25
See 35 U.S.C. §§ 101–03 (2000). But see Ong, supra note 1, at 2 (suggesting that the
“products of nature” objection has been used as a short form for rejecting a patent based on
failure to meet the other specified requirements for patentability: novelty, utility, and
nonobviousness). In Merck & Co. v. Olin Mathieson Chemical Corp., the court stated:
The Patent Act of 1952 as its predecessors [did], authorizes a
patent for “any new and useful . . . composition of matter . . . ,”
provided only that the conditions for patentability, which are specified
in succeeding sections, are met. There is nothing in the language of the
Act which precludes the issuance of a patent upon a “product of
nature” when it is a “new and useful composition of matter” and there
is compliance with the specified conditions for patentability. All of the
tangible things with which man deals and for which patent protection
is granted are products of nature in the sense that nature provides the
basic source materials. The “matter” of which patentable new and
useful compositions are composed necessarily includes naturally
existing elements and materials . . . .
A product of nature which is not a “new and useful . . . machine,
manufacture, or composition of matter” is not patentable, for it is not
within the statutory definition of those things which may be patented.
Even though it be a new and useful composition of matter it still may
be unpatentable if the subject matter as a whole was obvious within
the meaning of § 103, or if other conditions of patentability are not
satisfied.
253 F.2d 156, 161–62 (4th Cir. 1958).
26
See infra Parts II.A–C.
27
See infra Part II.D.
22
23
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with the patentability of genes.28 Finally, policy issues are relevant to
this discussion because they demonstrate current political interpretations
of the term “naturally occurring.”29
A. Short History of Genetics
Genes have played a role in the composition of life since the dawn of
time; however, it was not until recently that man has discovered them.30
The history of modern genetics began in 1863 when Gregor Mendel, in
his study of peas, discovered that traits are transmitted from parents to
progeny by independent units called genes. 31
His observations
established the groundwork for genetics.32 Close to one century later,
Oswald Avery, Colin MacLeod, and Maclyn McCarty published a paper
describing the transforming principle of genetic material as DNA,
beginning the era of molecular genetics.33 One of the largest discoveries
in the field of genetics, the discovery of the double helical structure of
DNA occurred in 1953 and is attributed to Watson and Crick.34 In the
past half century, the field of molecular genetics has progressed at an

See infra Part II.E.
See infra Parts II.F–G.
30
See Kelly Owens et al., Genomic Views of Human History, SCI., Oct. 15, 1999, at 451
(discussing the genetic controversies concerning several different populations including the
Nile Valley people and the Ashkenazi Jews from as early as 1991 BC); see also Robert
Koenig, Uphill Battle to Honor Monk who Demystified Heredity, SCI., Apr. 7, 2000, at 37
(discussing the work of Gregor Mendel from only 100 years ago, which can be considered a
short time in the history of evolution).
31
WILLIAM S. KLUG & MICHAEL R. CUMMINGS, CONCEPTS OF GENETICS 46 (Sheri L.
Snavely ed., 6th ed. 2000) (1997). Gregor Mendel’s obituary stated that he was a “man of
the noblest character, one who was a warm friend, a promoter of the natural sciences, and
an exemplary priest.” Id.
32
Id.
33
Id. at 287. Originally, protein was thought to be the biomolecule responsible for
heredity. Id. However, this paper was the first time DNA was offered with experimental
proof as the biomolecule responsible for heredity. Id.
34
Id. Watson lobbied for the creation of the Human Genome Project and in 1988 became
its director, a position he kept for the first four years. See
28
29
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are against the patenting of genes argue that the incentive of a patent is
unnecessary to encourage additional discovery or sequencing of genes
because research alone satisfies intellectual curiosity.141
The economic benefits of investment are another concern created by
the patentability of genes.142 When biotech prospectors are successful in
achieving a cure to a disease or developing a medicine, they stand to
make a large return on their initial investment. 143 Failure to grant a
patent to researchers and investors impairs investors’ ability to earn a
return on their investments. 144 As a result, funding from the private
sector could quickly dry up, and genetic research would be negatively
affected.145 Furthermore, investment in the field of genetic research is
already a risky concept.146 If public domain researchers are successful in
getting as much of their research as possible into the public domain, then
even though other discoveries may not have the ethical issues attached to them that genes
do, this fact should not be a basis to exclude a patent because other discoveries get the
benefit. Id.
141
Id. at 526. The race for scientific discovery is another motivator that could potentially
take the place of patents. See Ko, supra note 139, at 793.
142
Utility Examination Guidelines, 66 Fed. Reg. 1093, 1094 (Jan. 5, 2001). The Guidelines
specifically state the following:
[W]hen a patent claiming a new chemical compound issues, the
patentee has the right to exclude others from making, using, offering
for sale, selling, or importing the compound for a limited time. The
patentee is required to disclose only one utility, that is, teach others
how to use the invention in at least one way. The patentee is not
required to disclose all possible uses, but promoting the subsequent
discovery of other uses is one of the benefits of the patent system.
When patents for genes are treated the same as for other chemicals,
progress is promoted because the original inventor has the possibility
to recoup research costs, because others are motivated to invent
around the original patent, and because a new chemical is made
available as a basis for future research. Other inventors who develop
new and nonobvious methods of using the patented compound have
the opportunity to patent those methods.
Id.
143
Byron V. Olsen, The Biotechnology Balancing Act: Patents for Gene Fragments, and
Licensing the “Useful Arts”, 7 ALB. L.J. SCI. & TECH. 295, 298 (1997). There is a commercial
need to protect the investors. See Andrews, supra note 135 (quoting Lisa Raines, vice
president of government affairs at the Genzyme corporation in Cambridge, Massachusetts,
stating that “biotechnology companies must raise tens of millions of dollars years before
they have a marketable product, and patents provide the only assurance of being able to
profit in the event that high-risk research is successful”).
144
Barbara Looney, Should Genes be Patented? The Gene Patenting Controversy: Legal,
Ethical, and Policy Foundations of an International Agreement, 26 LAW & POL’Y INT’L BUS. 231,
234 (1994). Researchers have provided a significant benefit to society and should therefore
be rewarded by a return for their efforts. Id.
145
Id. at 244.
146
Id.
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private investors are likely to lose a substantial sum of money.147 If no
patent protection existed and competitors were free to imitate a genetic
product, prices would be driven down to the point that investors would
not make a return on their investments.148
The second argument regarding the concerns created by the
patentability of genes involves impairment of scientific research.149 This
argument can be broken down into several subsections that claim that
patents on genes actually impair, rather than promote, scientific
discovery. 150 The first subsection involves a waste of financial
resources. 151 Rebecca Eisenberg, a commentator on patenting genes,
argues that when a researcher wants to study a new gene related to a
gene that has already been claimed, the payment of royalties for use of
that gene constitutes a waste of resources.152 Such use should be open to
the public, and the money that would go to the payment of royalties
should go to some other use to promote scientific discovery.153

See Olsen, supra note 143, at 307. If a researcher gets his information out first, the
novelty requirement of § 102 is destroyed and the subsequent investor loses his investment.
Id.
148
See Looney, supra note 144, at 231. However, an argument could be made that even
with patent protection there remains competition prior to the patent stage to the point that
if another researcher wins the race to the patent finish line, the investor of the losing
researcher loses all of his investment with no chance of making any return. Id. At least in
the above stated instance, he would still have the chance to make some return depending
on the fierceness of the market competition. Id.
149
See John T. Bontivoglio & Martha Cochran, Policy Issues Could Have Major Impact on
Industry, NAT’L L.J., June 25, 2001, at C9 (discussing the problems created by patenting
genes on discrimination and privacy of healthcare on patients involved in genetic
research); Rebecca S. Eisenberg, Patenting the Human Genome, 39 EMORY L.J. 721, 742 (1990).
150
See Utility Examination Guidelines, 66 Fed. Reg. 1093, 1095 (Jan. 5, 2001) (discussing
the comments of several researchers expressing concern that DNA should be freely
available for research, patents are not necessary to encourage additional discovery, and
sequencing of genes and patenting of DNA inhibits biomedical research by allowing a
single person or company to control use of the claimed DNA). Furthermore, “patenting
ESTs will impede complete characterization of genes and delay or restrict exploration of
genetic materials for the public good.” Id.
151
See Eisenberg, supra note 149, at 737. Eisenberg argues that with the amount of federal
funding provided for genetic research, private funding is unnecessary. Id.
152
See Matthew Erramouspe, Staking Patent Claims on the Human Blueprint: Rewards and
Rent-Dissipating Races, 43 UCLA L. REV. 961, 996 (1996); see also McBride, supra note 140, at
526.
153
See Rebecca S. Eisenberg, Patents and the Progress of Science: Exclusive Rights and
Experimental Use, 56 U. CHI. L. REV. 1017, 1057 (1989); see also McBride, supra note 140, at
526.
147
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However, people who support the patentability of genes argue that
the payment of royalties serves a beneficial purpose.154 It encourages
incentive to design around the gene, which will actually further the goal
of the Patent Act.155 Furthermore, in the event that designing around a
gene is not possible, the researcher could develop a new process of
achieving its goal and obtain a patent on the process as opposed to the
composition.156 Proponents also argue that the field of research would
become inefficient. 157 In the absence of patent protection, several
researchers could independently be researching the same potential
invention, resulting in inefficient duplicative research and a waste of
funding. 158 When placed on a worldwide level, misappropriation of
resources proves to be severely inefficient.159
Researchers argue that another impairment on scientific research
created by the patentability of genes is secrecy in research labs. 160
Secrecy in the labs inhibits dissemination of important information,
slows progress, and ultimately limits the benefits to the public. 161
Furthermore, § 102 provides a statutory bar to anyone that publishes
information more than one year prior to the patent date, which also adds
to the secrecy in the labs. 162 However, others argue that the exact
opposite may be true. 163 Some researchers contend that the patent
system is beneficial to the scientific community because without it,

154
McBride, supra note 140, at 525. McBride offers four incentives that can be considered
to include the incentive of royalties: (1) incentive to invent, (2) incentive to disclose, (3)
incentive to commercialize, and (4) incentive to design around. Id.
155
Id. at 527–28. This concept is difficult to grasp. When a scientist wants to study the
effect of one gene upon another and either is already claimed by patent, it would seem
impossible to design around the patented gene when it is the exact entity that must be
studied. Id.; see Eisenberg, supra note 153, at 1026–27.
156
See Eisenberg, supra note 149, at 739 (arguing that it is difficult to prove and detect
process patent infringement); McBride, supra note 140, at 523–24; see also Eisenberg, supra
note 153, at 1028 (stating that patent protection may drive competitors to waste time and
money on duplicate situations to avoid infringement).
157
See Looney, supra note 144, at 236.
158
Compare Looney, supra note 144, at 236, with Olsen, supra note 143, at 323 (stating
patent protection actually runs the risk of inflating the price for research that can also be
considered a waste of resources).
159
Looney, supra note 144, at 236.
160
See Eisenberg, supra note 153, at 1028–30; Eisenberg, supra note 149, at 745; Looney,
supra note 144, at 237.
161
See Eisenberg, supra note 153, at 1028–30.
162
See 35 U.S.C. 102(b); see also Eisenberg, supra note 149, at 741.
163
See Eisenberg, supra note 149, at 741.
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scientists would be unprotected by a patent and would be forced to rely
on secrecy to protect their discoveries.164
Researchers argue that a final impairment on scientific research is the
potential abuse of genetic information.165 The large amount of money
invested in research and the desire to earn a return on these investments
creates a need to achieve a return in unethical ways.166 Many firms are
directing the information concerning genetic testing to the consumer and
completely bypassing the doctor/patient relationship. 167 Researchers
argue that such an approach will lead to a misuse of genetic testing and
unnecessary medical costs.168 Another potential abuse is that during the
licensing negotiations between certain researchers, a researcher may
refuse to issue a license due to personal bias or on the basis of a
professional threat. 169 Such occurrences could have a significantly
detrimental impact on further gene research. 170 Ethical arguments
regarding the abuse of genetic information are valid concerns, both
presently as well as in the future.171
The substantial backlog of gene applications in the USPTO is a final
concern arguably created by the patentability of genes.172 Researchers
have been rushing to identify as many gene sequences as possible to
secure rights over them in the event these sequences ultimately become
useful.173 Furthermore, the patentability of genes has spurred a race to
Id. at 742 (suggesting that this argument seems to disregard the fact that many
scientists work in the pursuit of knowledge and the attributed recognition that
accompanies a new discovery, not in the pursuit of dollars).
165
Lori Andrews & Erin Shaughnessy Zuiker, Ethical, Legal, and Social Issues in Genetic
Testing for Complex Genetic Diseases, 37 VAL. U. L. REV. 793, 814–15 (2003).
166
Compare Andrews & Zuiker, supra note 165, at 815, with Ong, supra note 1, at 6
(arguing that morality, ethical, and environmental concerns have no place in the patent
system), and Carrie F. Walter, Beyond the Harvard Mouse: Current Patent Practice and the
Necessity of Clear Guidelines in Biotechnology Patent Law, 73 IND. L.J. 1025, 1026 (1998)
(arguing that specialized commissions such as the National Bioethics Advisory
Commission are better suited to deal with the moral and ethical dilemmas presented by
biotechnology).
167
See Andrews & Zuiker, supra note 165, at 815.
168
Id. People will demand unnecessary and potentially more harmful tests from their
physicians when they meet little or none of the pre-screening criteria for such testing. Id.
169
See Eisenberg, supra note 153, at 1057.
170
Id.
171
Id.
172
Notice of Meeting and Request for Public Comments on Oversite of Genetic Testing,
64 Fed. Reg. 67,273, 67,275 (Dec. 1, 1999). From 1980 to 1999, over 12,000 patents had been
issued on plant, animal, and human genes; furthermore, applications had been filed for
another 30,000 genes. Id.
173
Looney, supra note 144, at 231.
164
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patent smaller pieces of DNA called express sequence tags (“ESTs”),
typically of unknown function, to serve as probes for known genes.174
Currently there are hundreds of thousands of applications waiting at the
patent office. 175 Such a backlog of genetic patents creates a problem
because other inventions have to wait a significantly long time to achieve
patent protection.176
Ultimately, the USPTO sides with those in favor of the patentability
of genes and strengthens this opinion by stating that isolated and
purified genes are patentable because they are not naturally occurring.177
However, the many different definitions of the terms “gene” and
“naturally occurring” may lead to discrepancies in the ways these terms
are applied to the Patent Act.178 Further analyzing these terms and their
application to the Patent Act may lead to the conclusion that genes
should not be patentable because they are naturally occurring.179
III. ANALYSIS
This Part begins by addressing the need to properly define the terms
“gene” and “natural” and presents the theory that the suggested
definitions would render genes unpatentable under the Patent Act. 180
Part III.B addresses previous case law considering the term “naturally
occurring” and provides possible outcomes resulting from the
application of the suggested definition of “natural” from Part II. 181
Finally, Part III.C offers solutions to the problems created by the
patentability of genes.182

174
See Arti Kaur Rai, Regulating Scientific Research: Intellectual Property Rights and the
Norms of Science, 94 NW. U. L. REV. 77, 104 (1999) (explaining that ESTs are little bits of gene
fragments and do not include the gene as a whole); see also Olsen, supra note 143, at 321–23
(discussing gene fragment patentability).
175
Human Genome Project Information, http://www.ornl.gov/sci/techresources/
Human_Genome/elsi/patents.shtml (last visited Jan. 31, 2005). Currently there have been
over three million genome-related patent applications filed at the USPTO. Id.
176
Id. “In the case of genetic patenting, it is the scope and number of claims that has
generated controversy.” Id.
177
See supra note 17 and accompanying text (discussing the USPTO’s inclusion of genes
into the Patent Act as compositions of matter, and further qualifying isolated and purified
genes as patentable subject matter because genes do not occur in nature in an isolated and
purified form).
178
See supra Parts II.B, II.E.
179
See infra Part III.A.
180
See infra Part III.A.
181
See infra Part III.B.
182
See infra Part III.C.
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A. Genes as Natural Phenomena
Although most definitions of the term “gene” agree that a gene is a
functional unit, many leave the biochemical definition of a gene open or
disagree on suggested definitions.183 The disagreement over the correct
definition creates a problem when the Patent Act is applied regarding
the non-naturally occurring statutory interpretation. 184 This Part
discusses the functional definition of a gene and suggests that a naturally
occurring function of a gene is to encode for specific aspects of
inheritance.185 Furthermore, this Part analyzes the physical definition of
a gene and the problems the current physical definitions present to § 101
and § 103 of the Patent Act. 186 Finally, this Part offers a uniform
definition of a gene in an attempt to resolve the problem created by the
discrepancies between the current definitions.187
To begin, almost all definitions of a gene state that a gene is a
functional unit of inheritance.188 This definition can be broadened to
suggest that a gene naturally serves as a functional unit of inheritance
because even when a gene is purified and isolated, it retains the natural
property of encoding for a particular polypeptide or other genetic
material. 189 Therefore, the functional characteristic of a gene is the
naturally occurring manifestation of the utility of the gene. 190 It is
unaltered through the process of isolation and purification and should
183
See supra note 52 and accompanying text (offering definitions of a gene as a sequence
coding for a polypeptide or an open reading frame of DNA). But see supra text
accompanying note 56 (offering a different definition of a gene as a specific chromosomal
locus).
184
See Ong, supra note 1, at 17 (noting the actual terms of the Patent Act and the
disqualification of organic substances because they are imprecise, mutable, inconstant, and
variable); see also Utility Examination Guidelines, 66 Fed. Reg. 1093, 1094 (Jan. 5, 2001)
(discussing the USPTO encompassment of genes as patentable subject matter by their
incorporation in the “composition of matter” provision of the patent act).
185
See infra notes 188–92 and accompanying text.
186
See infra notes 203–07 and accompanying text.
187
See infra notes 201–02 and accompanying text.
188
See supra text accompanying note 48; see also supra text accompanying note 52 (stating
that a gene is a sequence coding for a specific polypeptide); supra text accompanying note
55 (stating that a gene is a “unit of inherited material encoded by a strand of DNA”); supra
text accompanying note 58 (stating that a gene is a functional unit of inheritance controlling
the transmission and expression of one or more traits by specifying the particular structure
of a polypeptide).
189
See supra text accompanying note 81 (discussing that the function and performance of
a bacterium can relate to the “naturalness of the bacteria”); see also supra text accompanying
note 117 (discussing the patent board’s suggestion that a patent should not be issued unless
the product exhibited properties and utilities not possessed by the unpurified material).
190
See supra text accompanying note 48.
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therefore be considered naturally occurring. 191 If this definition is
applied to the Patent Act, a gene would not be patentable because it is
naturally occurring.192
Furthermore, the biochemical definition of a gene, which is its
physical description, also has discrepancies that must be addressed to
conclude that a gene is naturally occurring.193 In fact, it may be more
important to solve the discrepancies of the biochemical definition than
the discrepancies of the physical description because the term “naturally
occurring” has traditionally been applied to the physical description
rather than the function.194 Proof of this theory is offered through the
inclusion of the term “composition of matter” in the Patent Act, which
relates more to physical attributes than functional use.195
Yet another issue is that most definitions suggest an exact location of
the physical manifestation of a gene, i.e., the area of matter between start
and stop codons or a specific locus on a chromosome.196 However, these
definitions do not agree with each other and leave open the question as

191
See supra note 115 and accompanying text (discussing the isolation and purification
processes).
192
See supra text accompanying notes 67–72. The functional definition of a gene is not the
most important definition, but it must be addressed. See supra text accompanying note 48.
When considering what is naturally occurring, the mere tangible form of the substance is
considered more than the functional service of the substance. See supra note 112 (describing
physical products that are considered natural based on their physical being). Therefore,
although an object may serve a naturally occurring function, it may be a manmade and
altered substance, which would fulfill the requirements of the patent statute. See supra text
accompanying notes 112–13.
193
See supra notes 55–60 and accompanying text.
194
See supra text accompanying note 80 (discussing that the physical qualities of bacteria
are manifestations of nature); see also supra text accompanying note 113 (stating that a
patent could be secured for genetically engineered bacteria because they are non-naturally
occurring compositions of matter). The term “composition of matter” can allude to the
physical quality of a product as opposed to the functional quality of the product. See supra
text accompanying note 120 (stating that human hormones do not exist in nature in the
pure form). The term “form” relates to the physical manifestation rather than the
functional use. See supra notes 44–60 and accompanying text for a comparison between
“form” and “function.”
195
See 35 U.S.C. § 112 (2000) (“The phrase ‘composition of matter’ with respect to
granting application for patent covers all compositions of two or more substances and
includes all composite articles, whether results of chemical union or of mechanical mixture,
or whether they be gases, fluids, powders or solids.”). The terms used in the definition of
composition of matter describe the physical attributes but not the functional attributes of
the substance. See id.; see also 35 U.S.C. § 103.
196
See supra text accompanying note 56; see also supra text accompanying note 59
(discussing another definition suggesting that a gene includes the entire functional unit,
encompassing DNA sequences, non-coding regulatory sequences, and introns).
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to what exactly is the physical characteristic of a gene.197 The importance
in deciding this issue lies in the problems presented by the purification
and isolation techniques.198 Depending on which definition is applied,
the techniques may leave the gene unaltered and thus in its natural
state. 199 However, if the most specific definition is applied, the
components included beyond the functional unit may change, thereby
altering the gene as a whole.200
Based on this analysis, the most logical definition of a gene would
include the functional components (aspects that play a part in the role of
heredity) with the physical biochemical components (the actual
composition of the gene). The excess components, such as the noncoding regulatory DNA sequences, should be excluded from the
definition because they only play regulatory roles in the expression of
inheritance.201 The definition should define a gene in its narrowest sense,
which results in the conclusion that a gene does not qualify as patentable
subject matter.202
The suggested definition of a gene also fulfills the definitions of the
term “natural” and should therefore not be considered patentable. 203
The term “nature” has been defined as “the living world” and
everything within it that makes it up; however, this definition is
insufficient because it includes only the living world.204 One can imagine
several objects that are considered natural that do not fall in the category
See supra notes 48–53 and accompanying text.
See supra notes 4, 115 and accompanying text (discussing purification and isolation).
199
See supra text accompanying notes 48–60 (describing the different possible definitions
of a gene).
200
See supra notes 48–60. If the definition of a gene is simply the functional unit of the
gene, then the process of isolation and purification, which do not alter the functional
components, would leave the gene unaltered, thereby rendering the gene unchanged from
its natural state. See supra notes 48, 115 and accompanying text. However, if the more
specific definition is applied to include the encompassing DNA sequences, non-coding
regulatory sequences, and introns, these specific particles may be altered by the process of
isolation and purification. See supra note 59 and accompanying text. An alteration to these
components would thereby be an alteration to the gene because they are included in the
definition of what a gene entails. See supra notes 48–60. Therefore, the gene would no
longer occur in its “natural” state and would qualify to become patentable subject matter.
See supra notes 122–33 and accompanying text (discussing the term “natural”).
201
See supra note 59 and accompanying text.
202
By narrowing the suggested definition of a gene to only the functional components,
with functional relating only to the function of the DNA sequence that codes for the
specific protein, the gene will remain unaltered by the purification and isolation technique.
See supra text accompanying note 4.
203
See supra notes 122–33 and accompanying text.
204
See supra note 124 (discussing the definition from the DICTIONARY OF SCIENCE).
197
198
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of living.205 Another, more accurate, definition states that nature is the
genetically controlled qualities of an organism. 206 As stated in other
Parts of this Note, the process of isolation and purification does not alter
the actual genetics because the gene maintains its original function.207
Therefore, a gene can fit into the definition of a naturally occurring
product.208
A gene also qualifies as a natural phenomenon under philosophical
doctrines.209 Genes fit LaPorte’s theory that “naturalness” is promoted
by the explanatory value of the object because the reason for the gene is
explained by its functional definition.210 A gene is naturally comprised
of inheritance information, and this natural function precisely defines a
gene as a unit of hereditary information.211 Genes also fit Aristotle’s
definition of nature’s design and rational plan because the biochemical
design of a gene is a rational plan involving hereditary units that tell the
gene what to do.212 Finally, Lovejoy’s theory of nature, as that which
exists apart from and uninfluenced by man, can also be applied to genes
because the isolation and purification technique does not affect the gene
and its function at the most microscopic level.213 The gene remains in a
natural state regardless of this technique.214 Genes can qualify as natural
material based on philosophy as well as encyclopedic knowledge, and as
such, genes do not qualify as patentable subject matter.215

See supra note 124. For example, many of the smaller components of larger
manifestations of life, such as personality and physiology, which are not themselves living,
can be considered nature. See supra note 16 and accompanying text.
206
See supra note 124 (providing the definition from WEBSTER’S NEW WORLD
DICTIONARY).
207
See supra note 4 and accompanying text; see also supra note 115 and accompanying text.
208
See supra notes 122–33 and accompanying text.
209
See supra Part II.E.
210
See LAPORTE, supra note 125, at 18; see also supra note 126 and accompanying text
(discussing that the “natural” definition of an object is explained on the basis of why it does
what it does, why it has certain traits, and why it uses certain mechanisms).
211
See supra notes 48–53 and accompanying text (explaining the functional definition of a
gene).
212
See ALBERTS, supra note 46, at G15 (explaining the chemical composition of a gene and
its design as it relates to the functional purpose); see also supra notes 130–31 and
accompanying text; supra notes 132–33 and accompanying text (discussing Aquinas’s
expansion on Aristotle’s philosophy by incorporating the theory that nature is described as
the result of change).
213
See supra notes 128–29 and accompanying text (discussing Lovejoy’s theory of nature).
214
See supra note 115 and accompanying text.
215
See supra Part II.E.
205
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B. Differences in Court Opinions Regarding the Term “Naturally Occurring”
Analyzing court holdings regarding the term “naturally occurring”
further exemplifies that genes should not be considered patentable
subject matter. 216 Funk Brothers Seed 217 helps illustrate why genes are
naturally occurring because the bacteria in that case are comparable to
genes; they both contain the elements of life.218
The first pertinent aspect of the Court’s decision that is applicable to
genes is the holding that the qualities of the bacteria are works of
nature.219 The inventor in Funk Brothers Seed merely combined several
existent strains of bacteria to form one strain that performs a desired
task, which is comparable to the desired task of genes; when a gene is
purified and isolated, the underlying characteristics of the gene remain
unchanged.220 Regardless of how many genes are placed next to each
other, each separate gene performs its own, naturally derived function.221
The second area of importance in the Court’s decision that applies to
genes is that the bacteria performed the way nature intended;
furthermore, there was no improvement in their performance. 222
Although genes can be used for many improvements in the scientific
field, the use of the gene itself is not improved. 223 The gene only
performs the task that it was naturally intended to perform—coding for
a particular genetic trait.224

See supra Part II.D.
333 U.S. 127, 128 (1948).
218
Id. It can be argued that bacteria are alive and genes are just components that enable
life. In other words, bacteria contain genes. This argument does not change the underlying
contention of this Note because both occur naturally in the free world.
219
Id.
220
See supra note 4 and accompanying text. An almost universally accepted definition of
a gene encompasses the fact that a gene is a unit of inheritance of a genetic characteristic.
See supra notes 48–50 and accompanying text. The precise function and purpose of a gene
is therefore to display a certain characteristic. See KLUG & CUMMINGS, supra note 31, at 757
(implying that no matter what technique is used to obtain the gene, in its naturally
occurring state, it cannot result in a characteristic different from the one for which it
codes).
221
See supra notes 48–53 and accompanying text.
222
Funk Bros. Seed, 333 U.S. at 132.
223
See supra note 55 and accompanying text (describing a gene as a unit of inherited
material encoded by DNA that describes what the gene is supposed to do). This function is
not changed upon removal from noncoding regions of DNA. KLUG & CUMMINGS, supra
note 31, at 49.
224
See supra Part II.B (discussing the definition of how a gene functions).
216
217
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Public policy concerns are another area addressed by the courts
when dealing with naturally occurring products of nature. 225 The
holding in O’Reilly, that monopolization of electromagnetism is against
public policy, is also applicable to the potential monopolization of the
scientific community created by patenting genes.226 Just as the inventor
would be able to avail himself of any further discoveries using the power
of electromagnetism according to O’Reilly, so too may a researcher with a
patent on an important gene avail herself of any further discoveries
created from the use of that gene.227 A strong public policy argument
against allowing others to benefit from naturally occurring substances
remains when the public as a whole could receive an enormous benefit
from the substance.228
The conjecture made in O’Reilly that Fulton, the inventor of the
steam engine, could not have obtained a patent for the motive power of
steam because it would prevent further progress and improvement to
the engine is also applicable to the impairment on scientific research
created by patenting genes.229 When others are restricted from using a
gene, they are unable to make advances in scientific research.230 This
hindrance could have an overall detrimental effect on society because
society is not being availed of the latest technological advances.231
Although the holdings from Funk Brothers Seed and O’Reilly
demonstrate that genes should be considered naturally occurring, other
cases concerning the term are distinguishable. 232 The holding in
Chakrabarty is not applicable to genes even though bacteria and genes
may qualify as compositions of matter because, unlike the bacteria in
Chakrabarty, genes do not satisfy all other statutory requirements.233 One
See infra notes 83–92 and accompanying text.
See O’Reilly v. Morse, 56 U.S. 63, 113 (1854).
227
Id.; see also Eisenberg, supra note 153, at 1030 (discussing that the monopolization of
scientific products creates the problem of secrecy in the labs because researchers want to
achieve monopoly so they keep their work secret to society’s detriment).
228
See supra notes 160–61 and accompanying text.
229
See O’Reilly, 56 U.S. at 113.
230
See Eisenberg, supra note 153, at 1030.
231
See supra notes 161–69 and accompanying text (discussing the detrimental effect that
patentability of genes could present to society as a whole). Due to the large amount of
money invested in research, practitioners may behave unethically and administer
unnecessary genetic testing at a high rate to compensate for their investments. Id. This
may lead to an abuse of genetic testing and unnecessary medical costs. Id.
232
See supra Part II.D (discussing the difference in court opinions regarding the term
“naturally occurring”).
233
Diamond v. Chakrabarty, 447 U.S. 303, 305 (1980). One of the problems addressed by
the lower court was that living matter is not patentable. Id. at 305. Therefore, § 101 was not
225
226
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of the underlying statutory requirements for patentability is that the
objects to be patented must not naturally occur.234 Therefore, even if a
product fulfills the composition of matter requirement, it must also fulfill
all other requirements of patentable subject matter to qualify for a
patent.235 If it were determined that genes are naturally occurring, it
would make no difference whether they were compositions of chemical
matter; they would not fulfill all statutory requirements and would thus
not be patentable.236
This argument leads to the second reason the Court held
Chakrabarty’s bacteria patentable:
Chakrabarty had developed
genetically engineered bacteria by combining the DNA of two bacteria
into one.237 His feat was successful because he built a new object by
taking two different objects and putting them together.238 This technique
is different, in fact inapposite, to the technique used to obtain a gene.239
In order to obtain a gene, one must go into an already existing and
naturally occurring strand of DNA and excise the gene to be patented
applicable and a patent could not be issued. Id. However, the Supreme Court addressed
this issue and held that it is not a matter of deciding whether a product is living or
nonliving because living organisms, when created by man, can be patentable. Id. at 309.
When this argument is presented against the patenting of genes, one could suggest that
genes are components of living material that are not created by man. See supra notes 183–
214 and accompanying text. However, the aspect of living material verses the discussion of
living organisms is rather attenuated and provides little support to the argument. See
Chakrabarty, 447 U.S. at 308 (discussing the Court’s definition of “composition of matter” as
“all compositions of two or more substances and . . . all composite articles, whether they be
the results of chemical union, or of mechanical mixture, or whether they be gases, fluids,
powders or solids” ).
234
See 35 U.S.C.S. § 101 note 41; see also supra notes 67–71 and accompanying text
(discussing what qualifies as naturally occurring substances for patent invalidity).
235
The USPTO has held that genes qualify as “chemical compositions of matter” and are
therefore patentable. See supra text accompanying note 110 (stating that genes are chemical
compositions of matter and should not be treated differently than other compositions of
matter). However, the USPTO has also stated that as long as the gene’s chemical
composition meets all other statutory requirements, there is no legal basis to reject it. See
supra note 17 and accompanying text; see also Ong, supra note 1, at 2 (stating that even if an
organic compound qualifies as a “composition of matter,” if the core of the invention lies in
its natural function, it should be considered a product of nature); see supra notes 99–101,
110–13 (discussing the decision reached in Chakrabarty and the emphasis on other statutory
requirements).
236
See supra note 108 and accompanying text (discussing the definition of the term
“composition of matter”).
237
See Chakrabarty, 447 U.S. at 303.
238
Id. The key to this point in the analysis is that he performed addition to get the
genetically modified bacteria; he had to utilize addition of two naturally occurring
manifestations of nature, which by themselves would not qualify as patentable subject
matter, and combine them to make a form that had never existed before. Id.
239
Id.; see also supra note 4 and accompanying text.
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using an isolation and purification technique.240 The process requires the
invasion into an already naturally occurring object and pulling out a
component of it that is also in its naturally occurring state.241 It is much
easier to realize that one is creating or inventing a new item when he
combines two different naturally occurring objects into a non-naturally
occurring object, than it is to realize that one is creating an object when
he merely goes into a naturally occurring object and pulls an item out of
it.242
The next issue concerning the term “naturally occurring” is the
federal circuit’s holding that the isolation and purification technique
alters a natural product to the point that it can no longer be considered
natural. 243 In re Bergstrom discussed such a technique as applied to
human hormones; however, more emphasis should have been placed on
the patent board’s decision, which found that if the purified material did
not exhibit properties and utilities not possessed by the unpurified
material, it could not be issued a patent.244 This holding suggests that if
the properties of the pure form are the same as the properties of the
impure form, the pure form lacks the statutory requirement of novelty.245
Application of the patent board’s theory to genes should result in a
similar holding that genes should not be patentable.246 Genes satisfy the
utility requirements of the patent statute largely because of their
functions and physical uses in science and technology.247 In fact, it is
often the exact function and utility of the gene that makes it a desirable
subject for research in the first place.248 Because a gene has the same
240
See supra text accompanying note 17 (stating that the USPTO asserted that a DNA
strand by itself is raw, fundamental, non-descriptive information that alone is not
patentable).
241
See supra Part II.E.
242
Compare Chakrabarty, 447 U.S. at 303 (involving a process that required adding bacteria
together), with In re Bergstrom, 427 F.2d 1394, 1396 (C.C.P.A. 1970) (involving a process
where a purified product was pulled from an unpurified compound).
243
See supra note 17 (discussing the USPTO’s argument that such modification alters the
natural state of a gene to the point that it becomes manmade and thus patentable).
244
In re Bergstrom, 427 F.2d at 1396.
245
See supra notes 114–17 and accompanying text.
246
The board found that both the pure and impure materials could stimulate smooth
muscle cells and lower blood pressure. See supra text accompanying note 117. Likewise, a
gene that is purified and isolated will have the same characteristics and properties as an
impure gene in regards to the function of the gene, even though the actual physical
manifestation of the gene may be different. See supra text accompanying notes 4, 115.
247
See supra note 65 and accompanying text (discussing the requirement of utility as
being derived from the constitutional clause granting a patent for any new and useful
machine, manufacture, or composition of matter).
248
See supra notes 149–64 and accompanying text (discussing the research of genes for
genetic testing as well as the substantial investments that are offered for research to occur).
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function regardless of whether it is impure or pure and contains the
same genetic code in either form, the purified material does not exhibit
properties and utilities not possessed by the unpurified material. 249
Therefore, according to the patent board’s decision, a gene would not be
patentable subject matter.250
However, even though the CCPA overruled the patent board by
placing emphasis on the naturally occurring characteristics of the
hormones and determining that the hormones do not exist in nature in
the pure form, genes should not have the same fate.251 First of all, genes
do occur in a pure form in nature at the most microscopic level because
the fragments and extra attachment plaques that are removed by
isolation and purification are not considered a part of the gene in the
natural sense. 252 Therefore, the removal of these materials leaves the
original gene, as a whole, unaltered in an isolated and purified product,
and so it is natural to the point that it is not patentable subject matter.253
This argument also supports the second holding in In re Bergstrom, that
the pure and isolated form of the hormone do not occur in nature’s
storehouse.254 Relating this logic to genes, if it is determined that the
pure and isolated form of a gene occur in a natural state in the DNA of a
cell, then it follows that it occurs in nature’s storehouse. Ultimately, the

See supra Part II.B (describing the genetic composition of a gene and the relation of the
composition to the function of the gene).
250
See supra notes 114–17 and accompanying text.
251
In re Bergstrom, 427 F.2d 1394, 1396 (C.C.P.A. 1970); see supra notes 119–20 and
accompanying text; see also supra note 120 and accompanying text (stating that hormones
“do not exist in nature in the pure form,” are not in “nature’s storehouse,” and had not
been “previously known” to exist).
252
See supra note 17 (discussing the USPTO argument that genes are not natural in their
isolated and purified state and are therefore patentable subject matter); see also supra note
52 and accompanying text (using the definition of a gene as an open reading frame of a
sequence of DNA that is the region between the start and stop codons). When this
definition is applied, at the most microscopic level, a gene exists in a natural form. See
supra Part II.E.
253
See supra note 53. It is not the actual gene that is becoming altered, manipulated, and
changed to the point that it becomes manmade as the USPTO has suggested. See supra text
accompanying note 17. What is actually manipulated and altered are the fragments and
attachment material, which are not definitional parts of the gene. See supra Part II.B.
(describing the particles of a gene). Therefore, when looking only at the biochemical
makeup of the gene, the definitional gene occurs in the pure form in nature. This same
argument could pertain to the steroids in In re Bergstrom. See 427 F.2d at 1396. The
hormones themselves, on the most basic level, remain pure and isolated in the definitional
sense of the term “hormone.” See ALBERTS, supra note 46, at G12. Therefore, the actual
hormone is not altered, only the material around it is altered, and the hormone remains
pure in the most microscopic sense of the argument. Id. at 545.
254
See In re Bergstrom, 427 F.2d at 1395.
249
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inability of courts to withhold patents on naturally occurring substances
must be addressed to resolve the current problems associated with the
patentability of genes.255
C. Current Problems That Arise From Issuing Patents on Genes
One of the main reasons for excluding genes from patentable subject
matter on the basis of their natural occurrence is the public policy
problems presented by their current incorporation.256 The following Part
analyzes the different public policy arguments surrounding genes that
relate to the incentives for invention, economic benefits of investment,
impairment on scientific research, and a large backlog of the USPTO.257
Ultimately, the detriments of the patentability of genes outweigh the
benefits.258
First, the argument that the ability to issue a patent on human genes
is necessary to provide an incentive to perform research fails to take into
account the natural curiosity of mankind and the desire for the United
States to be the leading nation in science and technology.259 Competition
is a naturally driven characteristic of mankind that is not necessarily
sparked by incentive. 260 Furthermore, some of the most important
inventions have been successfully achieved without the incentive for
statutory monopolization.261 While incentive for invention may play a
role in the promotion of certain aspects of science and technology, when
See supra Part II.F.
See supra Part II.F.
257
See infra notes 259–75 and accompanying text.
258
See infra notes 259–75 and accompanying text.
259
See supra notes 142–48 and accompanying text; see also CHISUM, supra note 4, at 62
(discussing that the incentive to invent remains in achieving a patent and a monopoly on
the patented object); Eisenberg, supra note 149, at 721.
260
Mankind is naturally drawn to compete both intellectually as well as physically.
Cynthia Johnson, Children and Competition, 1993 N.C. COOPERATIVE EXTENSION SERV. J. 2,
available at http://www.ces.ncsu.edu/depts/fcsl/human/pubs/ses404.pdf. For example,
children start playing sports at an early age. Id. One of the underlying principles in most
sports is to fulfill the natural desire to compete. Id. This desire can also be placed on the
intellectual level by the desire for America’s youth to be successful in grade school spelling
bee championships or math competitions. Id.
261
The Great Idea Finder, Fascinating Facts About the Invention of the Wheel by
Mesopotamian’s in c3500 BC, https://www.ideafinder.com/history/inventions/wheel.
htm (last visited Feb. 22, 2005). The most classic invention would be the wheel, which was
evolutionarily invented to make transporting items easier. Id. The incentive in this
invention was to make life essentially easier, not to be granted control over the use and
future production of the product.
Id.
The suggestion presented here is that
monopolization is not the only incentive that drives people to develop extremely important
advances in technology and science. Id.
255
256
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the product in question is an item as important as the cutting edge of
biotechnological research, other incentives play a more powerful and
regulatory role than that achieved by monopolization of the product.262
The second set of arguments, that a patent is necessary to ensure a
return on investments and that funding from the private sector will
disappear because researchers and investors will have an impaired
ability to earn a return on their investments, does not acknowledge the
fact that many investments naturally incorporate risks.263 Even as patent
protection exists today, investing in genetic research is a risky venture
and it may only remotely be affected by the issuance of patent
protection. 264 Regardless of whether patent protection is offered, the
effect of scientific research will always be a race to discovery, and
whoever gets there first will most likely end up with the greatest
return.265
The third argument, that failing to allow the issuance of patents on
genes would impair scientific research, is without merit because the
issuance of patents is arguably what causes impairment to scientific
research.266 The concern that a patent is necessary to require a scientist to
pay expensive royalties to a patent-owning scientist is flawed because
expensive royalties waste significant financial resources and ultimately
take part of a valuable commodity away from the field of research.267
Such money should not be thrown back into an object that has already
been discovered. 268 Scientific research will continually be performed,
and the money used for royalties should be sent to other areas of
262
For example, when a product is not highly important to civilization and is without
patent protection, one may not wish to invest the time and effort into the fulfillment of the
invention; however, when the product is of such great importance to society, such as the
beneficial medical products of gene research, issuance of a patent may not be the necessary
incentive for invention. See Eisenberg, supra note 153, at 1028.
263
See Looney, supra note 144, at 234 (stating that researchers have provided a significant
benefit to society and should be rewarded by a large return on their investments of both
money and time).
264
See Erramouspe, supra note 152, at 996 (discussing that even with patent protection, an
underlying sense of competition remains in the field of research to be the first to discover
because if time and money is invested and someone else discovers first, the time and
money is lost).
265
Id. The opportunity to be the first to discover a workable gene and to put the function
of that gene into practice could arguably serve as an incentive for investment. Id. It is
likely that investors do not even incorporate the potential grant of a patent on the research
because being issued a patent is a risk in itself. Id. If one does not reach the finish line first,
he will not be issued a patent and all is lost to the investor. Id.
266
See supra notes 149–59 and accompanying text.
267
See supra note 152 and accompanying text.
268
See supra note 152 and accompanying text.
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undeveloped research to increase the speed with which these discoveries
surface and ultimately benefit society.269 Eliminating patents on genes
should have the effect of lowering the cost of research by eliminating
several thousands of dollars in attorney and filing fees, thereby
significantly lowering the cost involved when a scientist performs
further research on an already discovered product.270
The final argument, that genes should be excluded from patentable
subject matter because the USPTO is backlogged with hundreds of
thousands of applications at the office, survives scrutiny because the
beneficial impact of lowering the wait time for an application outweighs
the suggested impairments created by precluding the patentability of
genes. 271 Furthermore, if the current backlog of patents remains a
concern at the USPTO, the office may eventually need to hire a larger
staff, which would result in a much higher application fee for all
inventors wishing to claim a patent.272 High application fees may in turn
prohibit the applications of other useful inventions as well as raise the
cost of research on genes to an even higher level in order to cover the
application cost. 273 Such a result would surely hamper, rather than
promote, the field of discovery because few people would be able to
afford the very high application cost.274 The first step in preventing these
policy issues and diminishing the backlog at the USPTO is to remove
genes from the incorporation of patentable subject matter under the
Patent Act.275
Ultimately, the Patent Act needs to be amended to exclude genes
from patentable subject matter. For researchers and religious leaders, the
benefits of removing genes from patentable subject matter far outweigh
the detriments to investors and biotechnological companies. 276
Therefore, § 103 of the Patent Act should be amended to ensure that

See supra note 153 and accompanying text.
See supra notes 152–53 and accompanying text.
271
See supra notes 172–76 and accompanying text.
272
See Rai, supra note 174, at 104 (stating that a possible effect created by the patentability
of genes is higher application fees due to the need for a larger staff and a longer wait time
for issuance of patents). Furthermore, because of the extreme excess of applications
regarding highly complex gene sequences, higher educated employees with knowledge of
the subject matter will need to be hired, which can also increase the cost of the patent
system. Id.
273
Id.
274
Id.
275
See infra Part IV for a potential solution to the problems created by the patentability of
genes.
276
See supra Part II.F.
269
270
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society is not continually harmed by the problems created by the
patentability of genes.277
IV. PROPOSED AMENDMENT TO 35 U.S.C. § 103
As was discussed in Part III, allowing the patentability of genes is
detrimental to the Patent Act because genes are naturally occurring.278
Incorporating genes into the Patent Act undermines its goal of
rewarding invention because the incorporation of genes suggests that
material obtained without invention is also patentable.279 Furthermore,
the patentability of genes harms society by impairing scientific research
and preventing other worthy inventions from obtaining a patent in a
reasonable amount of time. 280 Consequently, this Note suggests an
amendment to § 103 of the Patent Act in an attempt to exclude genes
from patentable subject matter.281
To accomplish the removal of genes from patentable subject matter,
§ 103 of the Patent Act should be amended to exclude naturally
occurring objects and nucleotide sequences, and include a definition for
the term “composition of matter.” The amended statute appears as
follows, with the author’s commentary intertwined:
Proposed Amendment to 35 U.S.C. § 103282
(a) A patent may not be obtained though the invention is
not identically disclosed or described as set forth in
section 102 of this title, if the differences between the
subject matter sought to be patented and the prior art
are such that the subject matter as a whole is naturally
occurring or would have been obvious at the time the
invention was made to a person having ordinary skill in
the art to which said subject matter pertains.
Patentability shall not be negatived by the manner in
which the invention was made.

See supra Part IV.
See supra Part III.A.
279
See 35 U.S.C. § 101.
280
See Rai, supra note 174, at 104.
281
See infra notes 282–304 and accompanying text.
282
The proposals are the contributions of the author. Specifically, proposed additions are
italicized, and proposed deletions are struck out. The language in regular font is taken
from § 103. See generally 35 U.S.C. § 103.
277
278
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Commentary
To begin, because the courts have manipulated the term “naturally
occurring,” the term needs to be directly addressed in the Patent Act.283
Currently, the term “naturally occurring” is addressed as a condition
and requirement of the Patent Act and is discussed within previous court
opinions, where it is often only used as a last resort when an object is not
otherwise patentable under the novelty and nonobviousness
standards. 284
The incorporation of the precise term “naturally
occurring,” as well as a statutory definition, would ensure that the Patent
Act remains useful for the reasons it was written—to reward invention
and human ingenuity.285
Incorporation of the term “naturally occurring” in the
nonobviousness section of the Patent Act is the most logical place
because the two exclusions are very similar.286 Furthermore, eliminating
naturally occurring substances from patentable subject matter in the
actual text of the Patent Act, as opposed to just mentioning it in the
interpretive notes, will provide a clear rule for courts to apply.287 If a
court determines that an object is naturally occurring, it can
automatically exclude it, rather than use the term “naturally occurring”
as an excuse for unpatentability based on some other bar. 288 This
revision will lead to greater uniformity in the application of patent law to
naturally occurring substances.
(b)(1) Notwithstanding subsection (a), and upon timely
election by the applicant for patent to proceed under this

283

See CHISUM, supra note 4, at 62, which states:
The phrase “product of nature” is on occasion used in a different
sense—as a shorthand expression of the unpatentability under the
novelty and nonobviousness standards of (1) an old product derived
from a new source or process or (2) a new product that differs from old
ones only in terms of an incremental degree of purity.

Id.
284
See 35 U.S.C. § 101; see also supra notes 72–122 (discussing court decisions concerning
the term); supra note 4 (discussing the requirements for nonobviousness).
285
See 35 U.S.C. § 101.
286
See supra text accompanying note 4 (discussing the standard of nonobviousness as the
inability of one skilled in the art to obtain the invention upon a reasonable attempt).
Naturally occurring substances could arguably be considered obvious because they already
exist in nature.
287
Compare supra Part II.D (discussing the holdings of courts regarding the term
“naturally occurring”), with supra Part III.B (discussing the possible misapplications of the
term “naturally occurring” in several different cases).
288
See CHISUM, supra note 4, at 62.
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subsection, a biotechnological process using or resulting
in a composition of matter that is novel under section
102 and nonobvious under subsection (a) of this section
shall be considered nonobvious if—
(A) claims to the process and the composition of
matter are contained in either the same application for
patent or in separate applications having the same
effective filing date; and
(B) the composition of matter, and the process at the
time it was invented, were owned by the same person or
subject to an obligation of assignment to the same
person.
(2) A patent issued on a process under paragraph
(1)—
(A) shall also contain the claims to the composition
of matter used in or made by that process, or
(B) shall, if such composition of matter is claimed in
another patent, be set to expire on the same date as such
other patent, nothwithstanding section 154 [35 USCS
§ 154]289
(3) For purposes of paragraph (1), the term
“biotechnological process” means—
(A) a process of genetically altering or otherwise
inducing a single- or multi-celled organism to—
(i) express an exogenous nucleotide sequence,
(ii) inhibit, eliminate, augment, or alter expression of
an endogenous nucleotide sequence, or
(iii) express a specific physiological characteristic not
naturally associated with said organism;
Commentary
Eliminating the reference to a nucleotide sequence will prevent the
patenting of genes because genes consist of nucleotides.290 This section
references paragraph (1), which describes a nucleotide in these
circumstances as nonobvious.291 However, if the revision made in (a) is
accomplished, a nucleotide will be considered “naturally occurring” and
therefore not patentable.292 Maintaining (iii) supports the revision in (a),
289
No changes to section (2) are proposed. Section (2) above is the original text from the
statute. See 35 U.S.C. § 103(b)(2).
290
See supra Part II.B (discussing several definitions of genes, which include nucleotides).
291
35 U.S.C. § 101.
292
See supra Part III.A (discussing genes as natural objects).
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incorporating the term “naturally occurring” as obvious subject matter,
because it states that the characteristic must not naturally be associated
with the organism.
(B) cell fusion procedures yielding a cell line that
expresses a specific protein, such as a monoclonal
antibody; and
(C) a method of using a product produced by a
process defined by subparagraph (A) or (B), or a
combination of subparagraphs (A) and (B).
(4) For purposes of paragraph (1), the term “composition
of matter” means—
the manmade combination or mixing of elements or
ingredients. In order for a naturally occurring element to be
considered a “composition of matter,” it must be combined or
mixed through manmade manipulation techniques into a new,
non-naturally occurring form.
Isolated and/or purified
products do not qualify as “compositions of matter.”
Commentary
This revision will also exclude genes from patentable subject
matter.293 In order for a substance to be patented as a “composition of
matter,” it will have to result from the incorporation of two or more
naturally occurring elements into one non-naturally occurring element,
which would remove genes from this class of patentable subject matter
because the isolation and purification technique used in gene excision
does not leave a product that would meet this definition.294 The gene is
being taken from one piece of matter rather than added to other material.
The result of removing genes from patentable subject matter, as defined
by the Patent Act, will prevent many of the concerns regarding public
policy raised earlier in this Note.295
Care will be necessary in defining the term “composition of matter”
to retain many other biotechnological inventions worthy of
patentability.296 If the definition were to include the suggested elements,
then the bacteria in Chakrabarty would still qualify as patentable subject
See supra note 66 and accompanying text (describing the current incorporation of
genes into the Patent Act by qualifying them as compositions of matter). If this suggested
revision were applicable, genes would no longer fulfill this criteria.
294
See supra note 108 and accompanying text.
295
See supra Parts II.F, III.C (discussing the public policy arguments for and against the
patentability of genes).
296
See supra Part II.F.
293
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matter because two bacteria were combined together to form one
bacterium that performs in a non-naturally occurring way. 297 The
biotechnology corporations would be appeased because they could still
patent any biotechnological alteration involving the addition of
elements, which would therefore ensure a return on their investments.298
The main argument against redefining the term “composition of
matter” would be that not all biochemical inventions taken from one
piece of matter, rather than added to others, are genes; by eliminating
genes from patentable subject matter, many other inventions are also
eliminated.299 For example, the hormones in In re Bergstrom would no
longer qualify as patentable subject matter. 300 The hormones were
purified and isolated, thus rendering them patentable.301 However, the
same arguments regarding the term “naturally occurring” that apply to
genes can also apply to the hormones presented in In re Bergstrom.302
Based on the need to disqualify naturally occurring material from
patentable subject matter because of a lack of inventiveness, it can be
argued that these materials also should be disqualified.303 This revision
will help reinforce the ultimate goal of the Patent Act—to reward
invention by ensuring that only true inventions receive a patent.304
Ultimately, the proposed amendments to the Patent Act are
beneficial to society as a whole. People will only be issued patents on
material that they have invented, not merely excised from nature.
Therefore, the underlying premise for the Patent Act, to reward
invention with a monopoly for several years, will still be applicable.
Furthermore, biotechnology firms will still have a large array of
patentable material to work with, which ensures continued returns on
their research investments. A final beneficial impact created by the
proposed amendment is that the public policy concerns dealing with
297
See supra notes 99–100 and accompanying text (discussing the method of forming the
bacteria for the purpose of achieving the non-natural task of cleaning up oil spills).
298
See supra Part II.G (discussing the economic incentives argued to be created by the
patenting of biotechnological processes).
299
Basically any item obtained from the processes of purification and isolation would be
excluded. The same argument regarding “naturally occurring” can be applied to any
composition that is achieved by this process; however, based on the public policy issues
regarding the patentability of genes, this Note only addresses this issue.
300
See In re Bergstrom, 427 F.2d 1394, 1396 (C.C.P.A. 1970) (discussing the isolation and
purification technique used to purify hormones that were then considered patentable).
301
See supra notes 114–25 and accompanying text.
302
See Ong, supra note 1, at 16 (discussing the patentability of several biochemical
compositions).
303
Id.
304
35 U.S.C. § 101.
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patenting genes will finally be addressed. Therefore, the proposed
amendment should survive any threatening arguments.
V. CONCLUSION
The concerns raised by researchers and critics of gene patentability
addressing the ethical, legal, and moral implications of gene patenting
are real. As such, genes need to be removed from the category of
patentable subject matter. Genes can and should be removed because
they are not naturally occurring. The argument that genes are patentable
because they are purified and isolated, and thus altered to the point that
they are manmade, is without merit. The alteration and purification
technique does not change the underlying biochemical and functional
definition of a gene. Genes are naturally occurring, regardless of
whether they are in a purified and isolated state, and thus genes should
not be patented.
The way to solve this problem is to change the current Patent Act to
effectuate a greater understanding of the terms “natural” and
“composition of matter.” These definitions will ultimately result in more
uniform applicability of the Patent Act on a national level and will also
show biotechnology firms and others performing genetic research that
they need to find other ways to make a return on their investments.
Overall, the exclusion of genes from patentable subject matter under the
Patent Act and the establishment of genes as naturally occurring
manifestations of nature will have a beneficial impact on society and will
ensure that the Patent Act serves its original purpose—to reward
invention.
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